ES2174462T3 - Formulacion autoestimulante para compuestos lipofilos. - Google Patents

Formulacion autoestimulante para compuestos lipofilos.

Info

Publication number
ES2174462T3
ES2174462T3 ES98936887T ES98936887T ES2174462T3 ES 2174462 T3 ES2174462 T3 ES 2174462T3 ES 98936887 T ES98936887 T ES 98936887T ES 98936887 T ES98936887 T ES 98936887T ES 2174462 T3 ES2174462 T3 ES 2174462T3
Authority
ES
Spain
Prior art keywords
het
phenyl
so2nh
cyclopropyl
diglyceride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98936887T
Other languages
English (en)
Inventor
Walter Morozowich
Ping Gao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Pharmacia and Upjohn Co
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn Co, Upjohn Co filed Critical Pharmacia and Upjohn Co
Application granted granted Critical
Publication of ES2174462T3 publication Critical patent/ES2174462T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Nanotechnology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

Una composición farmacéutica que comprende: (a) un compuesto de piranona de fórmula II como agente farmacéuticamente activo. (b) una mezcla de diglicérido y monoglicérido en proporción de aproximadamente: 9:1 hasta aproximadamente 6:4 en peso (diglicérido:monoglicérido) donde el diglicérido y el monoglicérido son ésteres de glicerol y ácidos grasos mono- o di-insaturados, estando formados por una cadena de átomos de carbono con una longitud de entre dieciséis a veintidós átomos de carbono, (c) uno o más disolventes farmacéuticamente aceptables, y (d) de uno o más tensioactivos farmacéuticamente aceptables. Donde R1 es H; R2 es un radical alquilo C3-C5, fenil-(CH2)2-, het- SO2NH-(CH2)2-, ciclopropil-(CH2)2-, F-fenil-(CH2)2-, het- SO2NH-fenil, o F3C-(CH2)2-; o R1 y R2 tomados juntos forman un doble enlace; R3 es R4-(CH2)n-CH(R5)-, H3C-[O(CH2)2]2-CH2-, alquilo C3-C5, fenil(CH2)2, het-SO2NH-(CH2)2-, (HOCH2)3C-NH-C(O)- NH-(CH2)3-, (HO2C)(H2N)CH-(CH2)2-C(O)-NH-(CH2)3-, piperacin- 1-il-C(O)-NH-(CH2)3, HO3S(CH2)2-N(CH3)-C(O)-CH2)6-C(O)-NH- (CH2)3-, ciclopropil-(CH2)2-, F-fenil-(CH2)2- het-SO2NH- fenilo, o F3C-(CH2)2-; n es 0, 1 o 2; R4 es fenilo, het, ciclopropilo, H3C-[O(CH2)2]2-, het- SO2NH-, Br-, N3-, o HO3S(CH2)2-N(CH3)-C(O)-(CH2)6-C(O)-NH; R5 es CH2-CH3, o CH2-ciclopropilo; R6 es ciclopropilo, CH3-CH2-, o t-butilo; R7 es NR8SO2-het, -NR8SO2-fenilo, opcionalmente sustituido por R9, -CH2-SO2-fenilo, opcionalmente sustituido por R9, o CH2-SO2-het; R8 es -H, o CH3; R9 es CN, -F, -OH, o bien NO2; En la que het es un anillo insaturado o saturado de 5- , 6- o 7- miembros conteniendo desde 1 a 3 heteroátomos seleccionados de un grupo que contiene nitrógeno, oxígeno y azufre; e incluyendo cualquier grupo bicíclico en el que se ha condensado cualquiera de los anillos heterocíclicos anteriores con un anillo bencénico o a cualquier otro heterociclo, opcionalmente sustituido con CH3, -CN, -OH, - C(O)OCH2H5, -CF3, -NH2, o bien, -C(O)-NH2; o la sal farmacéuticamente aceptable del mismo.
ES98936887T 1997-07-29 1998-07-27 Formulacion autoestimulante para compuestos lipofilos. Expired - Lifetime ES2174462T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5407897P 1997-07-29 1997-07-29

Publications (1)

Publication Number Publication Date
ES2174462T3 true ES2174462T3 (es) 2002-11-01

Family

ID=21988649

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98936887T Expired - Lifetime ES2174462T3 (es) 1997-07-29 1998-07-27 Formulacion autoestimulante para compuestos lipofilos.

Country Status (22)

Country Link
US (2) US6531139B1 (es)
EP (1) EP0999838B1 (es)
JP (1) JP5005847B2 (es)
KR (1) KR100509130B1 (es)
CN (1) CN1113650C (es)
AT (1) ATE215370T1 (es)
AU (1) AU728695B2 (es)
BR (1) BR9810866B1 (es)
CA (1) CA2294032A1 (es)
DE (1) DE69804624T2 (es)
DK (1) DK0999838T3 (es)
ES (1) ES2174462T3 (es)
FI (1) FI20000171A7 (es)
HU (1) HU225160B1 (es)
NO (1) NO323773B1 (es)
NZ (1) NZ502567A (es)
PL (1) PL192080B1 (es)
PT (1) PT999838E (es)
RU (1) RU2203648C2 (es)
SI (1) SI0999838T1 (es)
SK (1) SK284579B6 (es)
WO (1) WO1999006043A1 (es)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE265847T1 (de) * 1997-07-29 2004-05-15 Upjohn Co Selbstemulgierbare formulierung enthaltend lipophile verbindungen
US7135191B2 (en) * 1997-09-04 2006-11-14 Zsolt Istvan Hertelendy Urogenital or anorectal transmucosal vaccine delivery system
GB9903547D0 (en) 1999-02-16 1999-04-07 Novartis Ag Organic compounds
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6956048B2 (en) 1999-03-31 2005-10-18 Pharmacia & Upjohn Company Pharmaceutical emulsions for retroviral protease inhibitors
DE60017720T2 (de) * 1999-03-31 2006-01-12 Pharmacia & Upjohn Co., Kalamazoo Pharmazeutische emulsionen für retroviral-protease hemmende verbindungen
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
GB9925127D0 (en) * 1999-10-22 1999-12-22 Pharmacia & Upjohn Spa Oral formulations for anti-tumor compounds
FR2805761B1 (fr) * 2000-03-02 2002-08-30 Mainelab Nanocapsules lipidiques, procede de preparation et utilisation comme medicament
KR20010100194A (ko) * 2000-03-13 2001-11-14 박호군 여러 가지 물질의 가용화용 조성물과 제형 및 그들의제조방법
US6623765B1 (en) * 2000-08-01 2003-09-23 University Of Florida, Research Foundation, Incorporated Microemulsion and micelle systems for solubilizing drugs
NZ526169A (en) * 2000-10-31 2005-12-23 Boehringer Ingelheim Pharma Oral dosage self-emulsifying formulations of pyranone protease inhibitors
KR20020066778A (ko) * 2001-02-13 2002-08-21 한국과학기술연구원 체내 난흡수 물질의 흡수촉진용 조성물과 제형 및 그의제조방법
US6680470B1 (en) * 2001-11-14 2004-01-20 Dicon Fiberoptics, Inc. Interleaver with thermal and chromatic dispersion compensation
AU2002351169B2 (en) * 2001-11-26 2007-09-20 Intas Pharmaceuticals Limited Method for preparing and using polyoxyethylated castor oil in pharmaceutical compositions
BR0214679A (pt) * 2001-12-03 2004-12-14 Novacea Inc Composições farmacêuticas compreendendo compostos a base de vitamina d ativa
US20030165545A1 (en) * 2002-01-30 2003-09-04 Allergan, Inc. Ophthalmic compositions including oil-in-water emulsions, and methods for making and using same
US6828301B2 (en) * 2002-02-07 2004-12-07 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for hepatitis C viral protease inhibitors
US20030199584A1 (en) * 2002-04-11 2003-10-23 Ahluwalia Gurpreet S. Reduction of hair growth
US7182950B2 (en) 2002-06-12 2007-02-27 Nutralease Ltd. Nano-sized self-assembled liquid dilutable vehicles
KR100533458B1 (ko) * 2002-07-20 2005-12-07 대화제약 주식회사 파클리탁셀의 가용화용 조성물 및 그의 제조 방법
US20050026877A1 (en) * 2002-12-03 2005-02-03 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
US20050196370A1 (en) * 2003-03-18 2005-09-08 Zhi-Jian Yu Stable ophthalmic oil-in-water emulsions with sodium hyaluronate for alleviating dry eye
US20060251685A1 (en) * 2003-03-18 2006-11-09 Zhi-Jian Yu Stable ophthalmic oil-in-water emulsions with Omega-3 fatty acids for alleviating dry eye
US20040185068A1 (en) * 2003-03-18 2004-09-23 Zhi-Jian Yu Self-emulsifying compositions, methods of use and preparation
US20040191332A1 (en) * 2003-03-27 2004-09-30 Allergan, Inc. Preserved ophthalmic compositions
US20050020546A1 (en) * 2003-06-11 2005-01-27 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
US20060003002A1 (en) * 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
GB0402679D0 (en) * 2004-02-06 2004-03-10 Novartis Ag Organic compounds
KR20050081092A (ko) * 2004-02-12 2005-08-18 한국과학기술연구원 생체적합성 친수성 고분자를 포함하는 콜로이드계 조성물,제형 및 이들의 제조 방법
WO2007063384A2 (en) * 2005-12-01 2007-06-07 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
WO2008058234A2 (en) * 2006-11-08 2008-05-15 Memory Pharmaceuticals Corporation Pharmaceutical formulations for 1,4-dihyrdropyridine compounds having improved solubility
EP2167493A1 (en) * 2007-03-09 2010-03-31 Novartis AG Salts of 3- (1h-ind0l-3-yl) -4- [2- (4-methyl-piperazin-i-yl) -quinazolin-4-yl]-pyrrole-2,5-di one
EP2164465A1 (en) * 2007-05-23 2010-03-24 Boehringer Ingelheim International GmbH Self-emulsifying formulation of tipranavir for oral administration
HU227873B1 (hu) * 2007-06-18 2012-05-29 Biogreen As Növényicsíra-alapú emulziók, eljárás az elõállításukra és alkalmazásuk
CA2686225A1 (en) * 2007-06-22 2008-12-31 Scidose Llc Solubilized formulation of docetaxel without tween 80
JP2011514349A (ja) * 2008-03-07 2011-05-06 サイドース・エルエルシー フルベストラント配合物
EP2257220B1 (en) * 2008-03-13 2017-06-14 Liebel-Flarsheim Company LLC Multi-function, foot-activated controller for imaging system
EA201100863A1 (ru) * 2008-11-28 2011-12-30 Эдванс Холдингз Лимитед Фармацевтическая композиция, включающая диклофенак и сложный эфир гидроксижирной кислоты и полиоксиалкилена
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
JP5607736B2 (ja) 2009-07-07 2014-10-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃ型肝炎ウイルスプロテアーゼ阻害剤のための医薬組成物
EP2488022B1 (en) 2009-10-16 2018-01-10 Mochida Pharmaceutical Co., Ltd. Compositions
US20110092579A1 (en) * 2009-10-19 2011-04-21 Scidose Llc Solubilized formulation of docetaxel
US8912228B2 (en) 2009-10-19 2014-12-16 Scidose Llc Docetaxel formulations with lipoic acid
US8541465B2 (en) * 2009-10-19 2013-09-24 Scidose, Llc Docetaxel formulations with lipoic acid and/or dihydrolipoic acid
US7772274B1 (en) 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
TWI438009B (zh) * 2010-02-19 2014-05-21 Teikoku Pharma Usa Inc 紫杉烷前－乳劑調配物及其製造與使用之方法
EA027666B1 (ru) 2010-05-03 2017-08-31 ТЕИКОКУ ФАРМА ЮСЭй, ИНК. Неводные лекарственные средства в форме проэмульсии на основе таксанов и способы их приготовления и использования
WO2012010942A2 (en) * 2010-07-22 2012-01-26 Lupin Limited Novel pharmaceutical composition(s) of hiv protease inhibitor(s)
US9468638B2 (en) 2010-09-24 2016-10-18 Texas Southern University Itraconazole formulations
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
US11179468B2 (en) 2012-04-09 2021-11-23 Eagle Pharmaceuticals, Inc. Fulvestrant formulations
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
US10711238B2 (en) 2012-10-02 2020-07-14 Repligen Corporation Method for proliferation of cells within a bioreactor using a disposable pumphead and filter assembly
US20160000799A1 (en) 2013-02-21 2016-01-07 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions of cetp inhibitors
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US20180015038A1 (en) * 2015-01-21 2018-01-18 Mochida Pharmaceutical Co., Ltd. Omega-3 fatty acid self-emulsifying composition
AU2016267685A1 (en) 2015-05-28 2017-12-07 Dr. Reddy's Laboratories Ltd. Oral composition of celecoxib for treatment of pain
US20160361322A1 (en) 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US11559530B2 (en) 2016-11-28 2023-01-24 Lipocine Inc. Oral testosterone undecanoate therapy
AU2019308326B2 (en) 2018-07-20 2025-07-31 Lipocine Inc. Liver disease
TWI676824B (zh) 2019-01-09 2019-11-11 友達光電股份有限公司 顯示裝置及顯示方法
CA3144079A1 (en) 2020-12-28 2022-06-28 Biodelivery Sciences International, Inc. Methods of treating pain

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4230702A (en) 1978-01-09 1980-10-28 Kali-Chemie Pharma Gmbh Readily enterally absorbable pharmaceutical compositions of per se poorly enterally absorbable pharmacologically active agents
JPS5618914A (en) * 1979-07-25 1981-02-23 Eisai Co Ltd Ubidecarenone composition having good absorbability
GB8903804D0 (en) * 1989-02-20 1989-04-05 Sandoz Ltd Improvements in or relating to organic compounds
US5639724A (en) * 1984-07-24 1997-06-17 Sandoz Ltd. Cyclosporin galenic forms
JPH0629180B2 (ja) * 1986-06-16 1994-04-20 エーザイ株式会社 吸収性の改良されたメナテトレノン含有組成物
DE3629386A1 (de) * 1986-08-29 1988-03-03 Scherer Gmbh R P Gelatinekapseln und verfahren zu ihrer herstellung
ES2042527T3 (es) * 1986-11-14 1993-12-16 Theratech Inc Un metodo para preparar una composicion farmaceutica aumentadora de la penetracion para la aplicacion topica.
JP2632010B2 (ja) * 1988-01-29 1997-07-16 三共株式会社 シクロスポリン製剤
GB2222770B (en) 1988-09-16 1992-07-29 Sandoz Ltd Pharmaceutical compositions containing cyclosporins
GB9113872D0 (en) * 1991-06-27 1991-08-14 Sandoz Ag Improvements in or relating to organic compounds
IL102236A0 (en) * 1991-06-27 1993-01-14 Ltt Inst Co Ltd Topical preparations containing cyclosporin
EP1142568A1 (en) * 1992-09-25 2001-10-10 Novartis AG Pharmaceutical compositions containing cyclosporins
WO1994008603A1 (en) * 1992-10-16 1994-04-28 Smithkline Beecham Corporation Compositions
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
IL129871A (en) * 1994-05-06 2003-11-23 Pharmacia & Upjohn Inc Process for preparing 4-phenyl-substituted octanoyl-oxazolidin-2-one intermediates that are useful for preparing pyran-2-ones useful for treating retroviral infections
EA001413B1 (ru) * 1995-06-06 2001-02-26 Ф. Хоффманн-Ля Рош Аг Фармацевтическая композиция, содержащая ингибитор протеиназы и моноглицерид
DE19537012A1 (de) * 1995-10-04 1997-04-10 Dietl Hans Cyclosporin(e) enhaltende pharmazeutische Zubereitung zur oralen Applikation und Verfahren zu ihrer Herstellung
ZA9710071B (en) 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.
ATE265847T1 (de) * 1997-07-29 2004-05-15 Upjohn Co Selbstemulgierbare formulierung enthaltend lipophile verbindungen

Also Published As

Publication number Publication date
HK1028877A1 (en) 2001-03-09
JP2002510329A (ja) 2002-04-02
DE69804624D1 (de) 2002-05-08
PT999838E (pt) 2002-07-31
RU2203648C2 (ru) 2003-05-10
HUP0003292A1 (hu) 2002-01-28
FI20000171L (fi) 2000-01-28
NZ502567A (en) 2002-03-28
PL338334A1 (en) 2000-10-23
US6531139B1 (en) 2003-03-11
HUP0003292A3 (en) 2002-02-28
KR20010022364A (ko) 2001-03-15
DE69804624T2 (de) 2002-09-19
NO20000465D0 (no) 2000-01-28
ATE215370T1 (de) 2002-04-15
CA2294032A1 (en) 1999-02-11
SK182000A3 (en) 2000-12-11
US6121313A (en) 2000-09-19
HU225160B1 (en) 2006-07-28
EP0999838B1 (en) 2002-04-03
AU728695B2 (en) 2001-01-18
WO1999006043A1 (en) 1999-02-11
NO20000465L (no) 2000-03-28
KR100509130B1 (ko) 2005-08-18
PL192080B1 (pl) 2006-08-31
SK284579B6 (sk) 2005-07-01
BR9810866A (pt) 2000-09-26
NO323773B1 (no) 2007-07-02
CN1261797A (zh) 2000-08-02
DK0999838T3 (da) 2002-07-08
AU8573798A (en) 1999-02-22
JP5005847B2 (ja) 2012-08-22
FI20000171A7 (fi) 2000-01-28
CN1113650C (zh) 2003-07-09
SI0999838T1 (en) 2002-08-31
EP0999838A1 (en) 2000-05-17
BR9810866B1 (pt) 2010-07-13

Similar Documents

Publication Publication Date Title
ES2174462T3 (es) Formulacion autoestimulante para compuestos lipofilos.
AR048642A1 (es) Compuestos de metil-aril o heteroaril-amida sustituida utiles como antagonistas del receptor de prostaglandinas e2; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento
ES2309410T5 (es) Nueva composición que contiene un compuesto bi-ciclico y un glicérido
RU2000104872A (ru) Самоэмульгирующаяся композиция для липофильных соединений
ECSP088457A (es) Compuestos de benzamida útiles como inhibidores de la histona deacetilasa
RU2012140961A (ru) ПРОИЗВОДНОЕ 1,3,4,8-ТЕТРАГИДРО-2Н-ПИРИДО[1,2-a]ПИРАЗИНА И ЕГО ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНИБИТОРА ИНТЕГРАЗЫ ВИЧ
AR046297A1 (es) Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo
AR018330A1 (es) Composiciones farmaceuticas que comprenden macrolidos como agentes activos para la terapia y profilaxis de las enfermedades de la piel
RU95117070A (ru) Производные циклоалкано-индола и -азаиндола, смесь их изомеров или отдельные изомеры и их соли, производные карбоновой кислоты в качестве исходных соединений для получения указанных производных и фармацевтическая композиция с антиатеросклеротической активностью
AR016725A1 (es) Compuestos derivados de isotiazol utiles como agentes anticancerosos, composiciones farmaceuticas, su uso en la preparacion de medicamentos y proceso para su preparacion
PE20011371A1 (es) Derivados de 3-(3-isopropil-5-metil-4h-1,2,4-triazol-4-il)-exo-8-azabiciclo[3.2.1]octano como antagonistas de los receptores de quimiocina ccr5
AR065937A2 (es) Compuesto derivado indazol, composicion farmaceutica que lo comprende y su uso en la fabricacion de medicamentos para modular la actividad de proteina quinasa
KR950005308A (ko) 직장투여용 조성물
PL191780B1 (pl) Kompozycja farmaceutyczna w postaci samoemulgującej formulacji związków lipofilowych i samoemulgujące podłoże formulacji
AR037882A1 (es) Cis-imidazolinas
AR041184A1 (es) Derivados de benzopiranonas, inhibidores de las cinasas dependientes de ciclinas y su uso
PE106099A1 (es) Uso de derivados hidroxicumaranonas sustituidos como agentes antitumorales y antimetastasicos
BR9810729B1 (pt) composição farmacêutica para compostos lipofìlicos ácidos disposta como uma formulação auto-emulsificante.
AR074352A1 (es) Acidos naftalen-2-il-aceticos sustituidos, composiciones farmaceuticas que los contienen, y uso de los mismos en el tratamiento de enfermedades alergicas,tales como rinitis, asma y dermatitis atopica.
AR020016A2 (es) Compuestos derivados de la eritromicina, composiciones que los contienen, uso de los mismos para preparar un medicamento
AR039190A1 (es) Derivados de benzofurano, composicion farmaceutica y medicamento que comprende el compuesto
RU2001118831A (ru) Макролиды, обладающие противовоспалительной активностью
AR074353A1 (es) Acidos naftalen-2-il-aceticos sustituidos, composiciones farmaceuticas que los contienen, y uso de los mismos en el tratamiento de enfermedades alergicas,tales como rinitis, asma y dermatititis atopica.
CA2424596A1 (en) Oral self-emulsifying formulations of pyranone protease inhibitors
AR089853A1 (es) Inhibidores de oxadiazol de la produccion de leucotrienos para terapia de combinacion, composicion farmaceutica, uso

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 999838

Country of ref document: ES